print_label | resize_label

RSViD Patient Risk
Assessment Tool

Assess pediatric patients for
risk of severe RSV disease.

Begin Assessment >

iAssist

iAssist is the streamlined
coordinator resource for
efficiently managing the
Synagis referral process.

Visit iAssist.com >

Synagis Dosing Calculator

Ensure your high-risk
patient gets the appropriate
dose of Synagis.

Calculate Synagis dose >

Information and tools to keep you informed and prepared

MedImmune offers a broad spectrum of Synagis resources, from informative videos for your practice to educational tearsheets for
parents and caregivers.

resources-thumb1
5:50
Synagis Mechanism of Action

Watch the mechanism of action for Synagis, the first monoclonal antibody successfully developed to help prevent an infectious disease.

resources-thumb2
9:57
Potential difficulties in obtaining Synagis

Watch Dr. Judy Bernbaum discuss the potential barriers many parents face in accessing Synagis for their infant.

Synagis Downloads

Educate parents and caregivers about RSV and why their babies may be high-risk. Most of the tools featured here are for your education, but the Synagis parent educational brochure is a helpful educational resource for parents. For printed samples, contact your MedImmune representative.

Important Safety Information

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). The recommended dose of Synagis is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of Synagis at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to Synagis. Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to Synagis. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to Synagis. The relationship between these reactions and the development of antibodies to Synagis is unknown. If a significant hypersensitivity reaction occurs with Synagis, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of Synagis. As with any intramuscular injection, Synagis should be given with caution to children with thrombocytopenia or any coagulation disorder. Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see full Prescribing Information for Synagis, including Patient Information.